CEO received an award of 17K CRL shares | OQRO Insider tradesWhy it stands out
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Mar 2, 2026
- Reporting period
- Not applicable
- Filed with the SEC
- Mar 4, 2026
CEOGrant / award
Context
- Classification
grant award
Code A — grant or award
- Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0001100682-26-000026
- Filed / recorded
Added to OQROOct 2, 2026, 12:27 PM UTC Data qualityVerified: identifiers matched exactly IssuerCHARLES RIVER LABORATORIES INTERNATIONAL, INC. Reporting personJames C Foster RelationshipDirector, Officer Officer titleChairman, President and CEO TableNon-derivative (Table I) Transaction dateMar 2, 2026 Acquired / disposedAcquired (A) Shares owned after279,693 Footnotes from the filing
- 100% of the unvested restricted stock units vest on March 2, 2028.
- Reflects the exempt transfer pursuant to Rule 16a-13 of 9,220 shares from the 2025 GRAT account to direct holdings.
Around the same time
Gift or transfer — classified separately from trades.
Charles River Laboratories's Corp Strategy & Develop spent $4.4K of their very own money to buy Charles River Laboratories shares.
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
